Business Wire

2025 NAB Show Wraps: Defines the Future of Media and Entertainment with Groundbreaking Innovation and Global Engagement

10.4.2025 01:44:00 CEST | Business Wire | Press Release

Share

The 2025 NAB Show concludes today as the leading global platform for the media and entertainment industry, reaching new audiences and connecting storytellers worldwide. With compelling industry insights, cutting-edge technology innovation, and a diverse global audience, this year’s event further cemented its role as the premier business event for professionals in the evolving landscape of content creation, broadcasting, and technology.

“The 2025 NAB Show truly exemplified the vibrant evolution of media and entertainment, debuting tools and technologies for all storytellers,” said Karen Chupka, executive vice president of NAB Show. “This year’s show provided a global platform for innovation, diverse voices, and forward-thinking conversations that will shape the future of storytelling and empower everyone to become a content creator.”

Global Reach

The 2025 NAB Show attracted 55,000 registered attendees from 160 countries. The show transformed the global reach for storytellers, with one out of four attendees traveling from outside the U.S. (26%), and 53% of participants registering for the first time. The growing presence of first-time registrants — more than half — reflects the expanding appeal and relevance of NAB Show on a global scale.

Show Trends and Exhibits

The show defined the future of the evolving media and entertainment landscape, with key trends such as artificial intelligence, the creator economy, and the intersection of sports and technology at the forefront.

NAB Show featured nearly 1,100 global exhibitors, including 125 first time exhibitors. Global brands included Adobe, AWS, AT&T Business, Canon, Cisco, Dell Technologies, Fujifilm, Intel, Microsoft, Nikon, Quantum Corporation, Riedel, Sony, and Verizon Business. The exhibit floor spanned more than eight soccer fields of innovation – reinforcing NAB Show as the hub for media and entertainment professionals worldwide.

“This is our Super Bowl,” said David Ross, CEO of Ross Video, a 2025 NAB Show exhibitor. “You've got to come to NAB - it's the biggest trade show in our industry. This is our chance to show the full breadth of our portfolio to all our customers.”

Top Speakers and Sessions

NAB Show brought together a broad spectrum of thought leaders, including representatives from major corporations like the Walt Disney Company, NBC Universal, TikTok, and YouTube. Top speakers included:

  • Gotham Chopra, Co-founder ROS (Religion of Sports)
  • Jody Gerson, Chairman and CEO of Universal Music Publishing Group
  • Nick Khan, President & CEO, WWE
  • Paul “Triple H” Levesque, Chief Content Officer, WWE
  • Dhar Mann and Sean Atkins from Dhar Mann Studios
  • Stephen A. Smith, Television Host, ESPN

The show featured more than 550 conference sessions and more than 1,000 speakers. The inclusion of new voices and fresh topics on the stage emphasized NAB Show’s commitment to providing a platform for innovation and forward-thinking discussions. Notable conference tracks included:

  • Sports Summit – This inaugural track explored the rapid convergence of sports, media, and technology, featuring insights from leaders such as Portia Archer, CEO of the Women’s Tennis Association.
  • Business of Entertainment - Produced in partnership with The Ankler, thought leaders addressed media dealmaking, content bundles, new advertising models, the state of production, and the intersection of Hollywood and the creator economy.

Sessions on topics such as AWS, AI, and sports streaming saw high attendance, demonstrating the industry’s growing demand for knowledge on emerging technologies. Additional highlights on the show floor included The Creator Lab, a dedicated space for digital creators to engage with new tools and resources to enhance their brands.

NAB Launches Creator Council

As a leading destination for storytelling and innovation, NAB has long been at the forefront of shaping the future of media, entertainment, and technology. This week, NAB took another significant step forward with the launch of its Creator Council. This new advisory group, composed of influential creators and thought leaders, is designed to amplify creators' voices and guide NAB’s engagement with the creator economy. With a focus on staying aligned with the evolving needs of creators, the council will provide strategic advice, helping NAB shape industry trends and continue to be a key player in the future of content creation.

Company Announcements

The 2025 NAB Show served as the backdrop for several major industry announcements. Sony announced its HDC-F5500V and the HDC-P50A. Verizon also announced its range of innovative solutions including a first-of-its-kind portable Private 5G Network framework designed to reduce pain points for live broadcasters.

Media Resources

Visit the NAB Show Gallery to download photos and videos from the show. For additional digital assets visit the NAB Show Media Kit and download the new NAB logo here. The redesigned logo reflects the evolving convergence of storytelling, technology, and innovation.

Stay Connected

For a detailed recap of the 2025 NAB Show, including key statistics and highlights, download the PDF here.

NAB Show returns to New York October 22- 23, 2025 and 2026 NAB Show returns to Las Vegas, April 18-22, 2026. Stay connected with the NAB Show community and follow NAB Show on YouTube, Instagram, X, LinkedIn, Facebook, TikTok, and Threads.

About NAB

The National Association of Broadcasters is the premier advocacy association for America’s broadcasters. NAB advances radio and television interests in legislative, regulatory and public affairs. Through advocacy, education and innovation, NAB enables broadcasters to best serve their communities, strengthen their businesses and seize new opportunities in the digital age. Learn more at www.nab.org.

About NAB Show

NAB Show is the preeminent conference and exhibition driving the evolution of broadcast, media and entertainment, held April 18-22, 2026 (Exhibits 19-22) in Las Vegas. Produced by the National Association of Broadcasters, NAB Show is the ultimate marketplace for next-generation technology inspiring superior audio and video experiences. From creation to consumption, across multiple platforms, NAB Show is where global visionaries convene to bring content to life in new and exciting ways. Learn more at NABShow.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250409613014/en/

Contacts

Sean Perkins - media@nabshow.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye